BR0308537A - Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga - Google Patents

Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga

Info

Publication number
BR0308537A
BR0308537A BR0308537-6A BR0308537A BR0308537A BR 0308537 A BR0308537 A BR 0308537A BR 0308537 A BR0308537 A BR 0308537A BR 0308537 A BR0308537 A BR 0308537A
Authority
BR
Brazil
Prior art keywords
hyperuricemia
diabetes
individual
compound
composition
Prior art date
Application number
BR0308537-6A
Other languages
English (en)
Inventor
Zuchun Zhao
Xin Chen
Jianchao Wang
Hongbin Sun
Jack Shih-Chieh Liang
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of BR0308537A publication Critical patent/BR0308537A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C07D249/20—Benzotriazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO, E MéTODOS PARA TRATAR DIABETES TIPO 2 E HIPERURICEMIA, PARA MODULAR RESISTêNCIA A INSULINA E PARA ALIVIAR HIPERLIPIDEMIA EM UM INDIVìDUO E AGENTE DE PRODROGA". São providos ácidos fenilacéticos substituídos, feniletanóis e compostos relacionados, que são úteis no tratamento ou controle de numerosas doenças associadas com o metabolismo da glicose, metabolismo de lipídeos e secreção de insulina.
BR0308537-6A 2002-03-20 2003-03-19 Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga BR0308537A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36696102P 2002-03-20 2002-03-20
PCT/US2003/008899 WO2003080545A2 (en) 2002-03-20 2003-03-19 Substituted phenylacetic acids

Publications (1)

Publication Number Publication Date
BR0308537A true BR0308537A (pt) 2005-02-09

Family

ID=28454828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308537-6A BR0308537A (pt) 2002-03-20 2003-03-19 Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga

Country Status (13)

Country Link
US (2) US7078421B2 (pt)
EP (1) EP1487843A4 (pt)
JP (1) JP2005520858A (pt)
KR (1) KR20050008661A (pt)
CN (2) CN100338073C (pt)
AU (1) AU2003237787B2 (pt)
BR (1) BR0308537A (pt)
CA (1) CA2479338A1 (pt)
MX (1) MXPA04009040A (pt)
NO (1) NO20044436L (pt)
NZ (1) NZ535603A (pt)
WO (1) WO2003080545A2 (pt)
ZA (1) ZA200407802B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
NZ547696A (en) 2003-12-23 2009-12-24 Astex Therapeutics Ltd Pyrazole derivatives as protein kinase modulators
CA2555814A1 (en) 2004-02-18 2005-09-01 Metabolex, Inc. Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
AU2005247473A1 (en) 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
US8008652B2 (en) * 2004-09-24 2011-08-30 Semiconductor Energy Laboratory Co., Ltd. Light emitting device
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
JP2008538351A (ja) * 2005-03-21 2008-10-23 メタボレックス インコーポレーティッド 癌を含むＰＰＡＲγ反応性疾患の処置または予防における浮腫を回避するための方法
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CN101282974A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的咪唑并吡啶衍生物
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
EP1948630A2 (en) * 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
WO2007068894A2 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008123349A1 (ja) * 2007-03-27 2008-10-16 Shionogi & Co., Ltd. Ｎ－フェニル－ｎ’－フェニルスルホニルピペラジン誘導体の製造方法
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009079683A1 (en) * 2007-12-21 2009-07-02 The University Of Sydney Translocator protein ligands
EA021424B1 (ru) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Тиазолопиридиновые соединения, регулирующие сиртуин
KR20130051507A (ko) 2010-09-15 2013-05-20 에프. 호프만-라 로슈 아게 아자벤조티아졸 화합물, 조성물 및 사용 방법
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
ES2597972T3 (es) 2011-02-08 2017-01-24 Pfizer Inc Modulador del receptor de glucagón
KR101395146B1 (ko) 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072585A (en) * 1960-01-13 1963-01-08 American Cyanamid Co Vinylbenzyloxy phenylbenzotriazoles
FR1451171A (fr) * 1961-04-21 1966-01-07 Jacques Logeais Soc D Expl Des Dérivés éthérifiés et estérifiés de l'o-hydroxy-phényl-2 oxadiazole-1, 3, 4 et leur procédé de préparation
US3444299A (en) 1964-02-07 1969-05-13 American Cyanamid Co Methods for the control and prevention of helminths with phenylbenzothiazolium compounds
GB1097053A (en) 1964-03-16 1967-12-29 Dow Chemical Co Substituted benzothiazolium compounds and complexes thereof for use in animal husbandry
US3558778A (en) 1966-10-27 1971-01-26 Dow Chemical Co Methods and compositions for use in animal husbandry
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
BE754245A (fr) 1969-08-01 1970-12-31 Sumitomo Chemical Co Derives d'acides phenoxy carboxyliques
FR2082478A5 (pt) * 1970-03-17 1971-12-10 Thomson Csf
GB1341222A (en) * 1970-04-17 1973-12-19 Takeda Chemical Industries Ltd Oxadiazole derivatives
DE2358789A1 (de) * 1973-02-07 1975-06-05 Merck Patent Gmbh Hydratropasaeure-derivate und verfahren zu ihrer herstellung
US4053626A (en) * 1973-03-13 1977-10-11 Merck Patent Gesellschaft Mit Beschrankter Haftung Cholesterol level-lowering phenoxyacetic acids
IL44356A (en) * 1973-03-13 1977-10-31 Merck Patent Gmbh Phenoxyacetic acid derivatives and processes for their preparation
US3876791A (en) 1973-11-30 1975-04-08 Uniroyal Inc Control of acarids using certain benzothiazoles or benzothiazolines
DE2415867A1 (de) * 1974-04-02 1975-10-09 Merck Patent Gmbh Phenoxyalkanolderivate und verfahren zu ihrer herstellung
US3894057A (en) * 1974-05-28 1975-07-08 Hoechst Co American Tetrahydrobenzofuranylphenoxycarboxylic acids, esters
US4001268A (en) 1974-08-07 1977-01-04 The United States Of America As Represented By The Secretary Of The Air Force Substituted phenyl-benzimidazo compounds
JPS6039072B2 (ja) 1976-07-28 1985-09-04 藤沢薬品工業株式会社 Ｎ−置換フエニルアミノ脂肪酸誘導体
JPS5371071A (en) 1976-12-08 1978-06-24 Teijin Ltd Alpha-phenoxyacetic acid derivs.
BE883069A (fr) 1979-05-04 1980-08-18 Continental Pharma Derives de phenylethylamine, leur preparation et utilisation ainsi que composition contenant ces derives.
US4508882A (en) 1981-08-24 1985-04-02 Asahi Glass Company Ltd. Benzotriazole compound and homopolymer or copolymers thereof
EP0077938A3 (en) * 1981-10-23 1983-08-24 Mitsubishi Kasei Corporation N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition
DE3236730A1 (de) 1982-10-04 1984-04-05 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von benzoxazolyl- und benzthiazolyloxyphenoxypropionsaeurederivaten
US4528311A (en) 1983-07-11 1985-07-09 Iolab Corporation Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles
JPS60109578A (ja) * 1983-11-17 1985-06-15 Mitsubishi Chem Ind Ltd ３−（置換フエニル）−５−置換−１，３，４−オキサゾリン−２−オン類およびこれを有効成分とする除草剤
JPS6140266A (ja) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
JPS6140270A (ja) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
JPH0670025B2 (ja) 1987-08-07 1994-09-07 鐘紡株式会社 ベンゾチアゾ−ル誘導体および該化合物を有効成分とする抗リウマチ剤
GB8720365D0 (en) 1987-08-28 1987-10-07 Sandoz Ltd Organic compounds
US4863802A (en) 1987-12-31 1989-09-05 General Electric Company UV-stabilized coatings
JPH01305069A (ja) 1988-05-31 1989-12-08 Shionogi & Co Ltd ベンゾトリアゾール誘導体およびそれを含有する発螢光試薬
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
US5281571A (en) * 1990-10-18 1994-01-25 Monsanto Company Herbicidal benzoxazinone- and benzothiazinone-substituted pyrazoles
US5278314A (en) 1991-02-12 1994-01-11 Ciba-Geigy Corporation 5-thio-substituted benzotriazole UV-absorbers
DE4303676A1 (de) * 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
EP0617001B1 (en) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
US5874431A (en) 1993-08-28 1999-02-23 Cancer Research Campaign Technology Limited Benzazole compounds
EP0774965A4 (en) * 1994-08-08 1997-10-29 Merck & Co Inc PHENOXYPHENYLACETIC ACID DERIVATIVES
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5455152A (en) 1994-09-27 1995-10-03 Eastman Kodak Company Benzotriazole based UV absorbing monomers and photographic elements containing polymers formed from them
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
US5500332A (en) 1995-04-26 1996-03-19 Eastman Kodak Company Benzotriazole based UV absorbers and photographic elements containing them
US5766834A (en) 1996-05-17 1998-06-16 Eastman Kodak Company Photographic element containing ultraviolet absorbing polymer
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
EP0839808A1 (en) * 1996-10-29 1998-05-06 Novartis AG Pyrazole derivatives, processes for their preparation, and their use as herbicides
AU722305B2 (en) 1996-11-22 2000-07-27 Ciba Specialty Chemicals Holding Inc. Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of UV radiation
JP3714574B2 (ja) 1997-03-26 2005-11-09 ダイセル化学工業株式会社 紫外線吸収剤とその製造方法および合成樹脂組成物
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
AU738772B2 (en) 1997-11-07 2001-09-27 Taiho Pharmaceutical Co., Ltd. Benzimidazole derivatives and pharmaceutically acceptable salts thereof
WO1999058521A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6013659A (en) 1998-09-04 2000-01-11 University Of Pittsburgh Methods of reducing tumor colony number using novel benzothiazole compounds
EE200100323A (et) 1998-12-18 2002-08-15 Axys Pharmaceuticals, Inc. (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
EP1162196A4 (en) 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
DE10014645A1 (de) * 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte Biphenylderivate
US7144896B2 (en) * 2002-03-18 2006-12-05 Merck Frosst Canada Ltd. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors

Also Published As

Publication number Publication date
US7642358B2 (en) 2010-01-05
AU2003237787B2 (en) 2008-12-18
EP1487843A2 (en) 2004-12-22
US7078421B2 (en) 2006-07-18
KR20050008661A (ko) 2005-01-21
CA2479338A1 (en) 2003-10-02
NZ535603A (en) 2007-10-26
WO2003080545A3 (en) 2004-01-22
WO2003080545A2 (en) 2003-10-02
US20040029933A1 (en) 2004-02-12
AU2003237787A1 (en) 2003-10-08
ZA200407802B (en) 2006-11-29
JP2005520858A (ja) 2005-07-14
MXPA04009040A (es) 2005-01-25
US20060264630A1 (en) 2006-11-23
NO20044436L (no) 2004-12-06
CN1653073A (zh) 2005-08-10
CN100338073C (zh) 2007-09-19
EP1487843A4 (en) 2010-03-10
CN101172983A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
NO20044436L (no) Substituerte fenyleddiksyrer
BR0314799A (pt) Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
BRPI0414146A (pt) aparelho para o controle da glicose no sangue
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR9906813A (pt) Método para administração de insulina aspb28- humana
MY142830A (en) Propionic acid derivatives useful in the treatment of lipid disorders
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
SG149814A1 (en) Compositions and methods for treating diabetes
WO2003061768A3 (fr) Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaircir la peau
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0506791A (pt) método para imitar uma resposta à insulina de primeira fase refeição-relacionada fisiológica em diabetes do tipo 2
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NZ512219A (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
DK1465641T3 (da) Lægemidler indeholdende deuterium til behandling af sukkersyge

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 513/00, C07D 498/00, C07D 291/04, C07D 291/08, C07D 271/02, C07D 271/12, A61K 31/40, A61K 31/41, A61K 31/4164, A61K 31/47, A61P 3/00

Ipc: C07D 513/00 (2011.01), C07D 498/00 (2011.01), C07D

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.